SB 202190 CAS: 152121-30-7
MF: C20H14FN3O
MW: 331.34
An inhibitor of the isoforms p38α and p38β.

SB 202190 (CAS 152121-30-7)

SB 202190 | CAS 152121-30-7 is rated 5.0 out of 5 by 1.
  • y_2020, m_3, d_30, h_12
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202334, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 131ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole
Application: An inhibitor of the isoforms p38α and p38β
CAS Number: 152121-30-7
Purity: ≥98%
Molecular Weight: 331.34
Molecular Formula: C20H14FN3O
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

SB 202190 is a pyridinyl imidazole that inhibits the p38 pathway. The compound inhibits the isoforms p38α and p38β. SB 202190 has displayed the ability to activate CPP32-like caspases and induce apoptosis. Research demonstrates that when one residue of ERK2, a related p38 not inhibited by pyridinyl imidazoles, is changed it allows SB 202190 to bind. Studies have revealed that SB 202190 can improve leukemia cell growth by activating MEK/MAPK, as well as phosphorylate and activate MLK3.


References

1. Jiang, Y., et al. 1996. J. Biol. Chem. 271: 17920-17926. PMID: 8663524
2. Nemoto, S., et al. 1998. J. Biol. Chem. 273: 16415-16420. PMID: 9632706
3. Fox, T., et al. 1998. Protein Sci. 7: 2249-2255. PMID: 9827991
4. Warrior, U., et al. 1999. J Biomol Screen. 4: 129-135. PMID: 10838421
5. Muniyappa, H. and Das, K.C. 2008. Cell. Signal. 20: 675-683. PMID: 18222647
6. Hirosawa, M., et al. 2009. Leuk. Res. 33: 693-699. PMID: 18995898

Physical State :
Solid
Solubility :
Soluble in DMSO (66 mg/ml at 25° C), methanol, DMF (~10 mg/ml), water (<1 mg/ml at 25° C), and ethanol (32 mg/ml at 25° C).
Storage :
Store at -20° C
Melting Point :
240-243° C
Boiling Point :
565.71° C at 760 mmHg (Predicted)
Density :
1.31 g/cm3 (Predicted)
Refractive Index :
n20D 1.65 (Predicted)
IC50 :
p38α: IC50 = 14.3 nM (human); p38 MAP kinase: IC50 = 30 nM; 5-LO: IC50 = 50 nM (human); p38 β: IC50 = 100 nM; Toxoplasma gondii: IC50 = 1 µM
Ki Data :
p38α: Ki= 5.01 nM (human); JNK3: Ki= 63.1 nM (human); JNK2: Ki= 0.25 µM (human); JNK1: Ki= 0.50 µM (human); ROR2: Ki= 0.79 µM (human)
pK Values :
pKa: 11.75 (Predicted), pKb: 9.37 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
5353940
MDL Number :
MFCD00941964
SMILES :
C1=CC(=O)C=CC1=C2NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

SB 202190  Product Citations

See how others have used SB 202190. Click on the entry to view the PubMed entry .

Citations 1 to 10 of 28 total

PMID: # 30731136  Höllerhage, M. et al. 2019. Neuropharmacology. 149: 13-26.

PMID: # 30422386  Gemperle, J.|Dibus, M.|Koudelková, L.|Rosel, D.|Brábek, J.| et al. 2019. Mol Oncol. 13: 264-289.

PMID: # 30365043  Dolivo, DM. et al. 2019. Int. J. Mol. Med. 43: 325-335.

PMID: # 30735839  Rahman, A.|Pallichankandy, S.|Thayyullathil, F.|Galadari, S.| et al. 2019. Free Radic. Biol. Med. 134: 527-544.

PMID: # 29791903  Onyiah, JC. et al. 2018. J Innate Immun. 10: 228-238.

PMID: # 30010083  Wang, Y.|Kim, J.|Chan, A.|Whyne, C.|Nam, D.| et al. 2018. Bone. 116: 47-57.

PMID: # 29435437  Chiarella, P. et al. 2018. Front Oncol. 8: 6.

PMID: # 28492699  Nocella, C.|Carnevale, R.|Bartimoccia, S.|Novo, M.|Cangemi, R.|Pastori, D.|Calvieri, C.|Pignatelli, P.|Violi, F.| et al. 2017. Thromb. Haemost. 117: 1558-1570.

PMID: # 28747804  van der Linden, M. et al. 2017. Sci Rep. 7: 6529.

PMID: # 28396222  Zhang, L.|Xu, P.|Wang, X.|Zhang, M.|Yan, Y.|Chen, Y.|Zhang, L.|Zhang, L.| et al. 2017. Int. J. Biochem. Cell Biol. 87: 69-76.

Citations 1 to 10 of 28 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 102ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Mayr Mayr, M. et al. (PubMed 10660448) used SB 202190, an inhibitor of the p38 pathway, to study the effects of p38 MAPKs on stress induced apoptosis in vein grafts. Introduction of SB 202190 prevented stress induced apoptosis in vein grafts. -SCBT Publication Review
Date published: 2015-07-10
  • y_2020, m_3, d_30, h_12
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202334, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 11ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.